Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO)

被引：0
|
作者：
Christel Fontaine
Vincent Renard
Heidi Van den Bulk
Peter Vuylsteke
Philip Glorieux
Catherine Dopchie
Lore Decoster
Leen Vanacker
Evandro de Azambuja
Jacques De Greve
Ahmad Awada
Hans Wildiers
机构：
[1] Oncologisch Centrum,Medical Oncology Department
[2] UZ Brussel,Medical Oncology Department
[3] AZ Sint-Lucas,Medical Oncology Department
[4] Imelda ziekenhuis,Medical Oncology Department
[5] CHU UCL Namur,Medical Oncology Department
[6] Cliniques Sud-Luxembourg,Medical Oncology Department
[7] Medical Oncology Department,Department of General Medical Oncology and Department of Oncology
[8] Institut Jules Bordet,undefined
[9] L’Université Libre de Bruxelles (U.L.B),undefined
[10] University Hospitals Leuven,undefined
来源：
Breast Cancer Research and Treatment | 2019年 / 176卷
关键词：
Triple-negative early breast cancer; Neoadjuvant chemotherapy; Weekly carboplatin and paclitaxel; Phase 2 trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：607 / 615
页数：8
相关论文
共 50 条
  • [1] Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO)
    Fontaine, Christel
    Renard, Vincent
    Van den Bulk, Heidi
    Vuylsteke, Peter
    Glorieux, Philip
    Dopchie, Catherine
    Decoster, Lore
    Vanacker, Leen
    de Azambuja, Evandro
    De Greve, Jacques
    Awada, Ahmad
    Wildiers, Hans
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2019, 176 (03) : 607 - 615
  • [2] A prospective phase II clinical trial identifying the optimal regimen for carboplatin plus standard backbone of anthracycline and taxane-based chemotherapy in triple negative breast cancer
    Hamm, Caroline
    Fifield, Bre-Anne
    Kay, Amin
    Kulkarni, Swati
    Gupta, Rasna
    Mathews, John
    Ferraiuolo, Rosa-Maria
    Al-Wahsh, Huda
    Mailloux, Emily
    Hussein, Abdulkadir
    Porter, Lisa A.
    [J]. MEDICAL ONCOLOGY, 2022, 39 (04)
  • [3] A prospective phase II clinical trial identifying the optimal regimen for carboplatin plus standard backbone of anthracycline and taxane-based chemotherapy in triple negative breast cancer
    Caroline Hamm
    Bre-Anne Fifield
    Amin Kay
    Swati Kulkarni
    Rasna Gupta
    John Mathews
    Rosa-Maria Ferraiuolo
    Huda Al-Wahsh
    Emily Mailloux
    Abdulkadir Hussein
    Lisa A. Porter
    [J]. Medical Oncology, 2022, 39
  • [4] SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer
    Xu, Lu
    Che, Xiaofang
    Wu, Ying
    Song, Na
    Shi, Sha
    Wang, Shuo
    Li, Ce
    Zhang, Lingyun
    Zhang, Xinlian
    Qu, Xiujuan
    Teng, Yuee
    [J]. ONCOLOGY REPORTS, 2018, 39 (05) : 2315 - 2323
  • [5] Neoadjuvant phase II trial with eribulin and carboplatin in patients with triple-negative breast cancer
    Giordano, Sara Barnato
    Rao, Shreyas
    Hamdan, Randala
    Jeruss, Jacqueline
    Bethke, Kevin
    Hansen, Nora
    Khan, Seema
    Von Roenn, Jamie
    Rosen, Steven
    Gradishar, William J.
    Siziopikou, Kalliopi
    Meservey, Caitlin
    Kaklamani, Virginia
    [J]. MOLECULAR CANCER RESEARCH, 2013, 11
  • [6] Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival inBRCA1/2-mutated triple-negative breast cancer
    Zhang, Juan
    Yao, Lu
    Liu, Yiqiang
    Ouyang, Tao
    Li, Jinfeng
    Wang, Tianfeng
    Fan, Zhaoqing
    Fan, Tie
    Lin, Benyao
    Xie, Yuntao
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2021, 148 (04) : 941 - 949
  • [7] Evaluation of weekly paclitaxel plus carboplatin followed by anthracycline chemotherapy on the neoadjuvant treatment of patients with triple-negative breast cancer
    Castrellon, A. B.
    Velez, M.
    Blaya, M.
    Barnick, S.
    Dumais, K.
    LeCroy, N.
    [J]. CANCER RESEARCH, 2017, 77
  • [8] Pathologic response to neoadjuvant therapy with nabpaclitaxel plus carboplatin followed by anthracycline regimen in triple-negative breast cancer.
    David Cardenas, Juan
    Esteban, Carmen
    Garcia Carbonero, Iciar
    Rosero, Adriana
    Martinez Barroso, Katherin
    Borrecion Rivilla, Miguel
    Rubio Salvador, Ana Rosa
    Aguilar Anqulo, Paul Martin
    Garcia Avila, Maria
    Ignacio Chacon, Jose
    Ruiz Martin, Juan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Phase II neoadjuvant trial with carboplatin and eribulin mesylate in patients with triple-negative breast cancer
    Barnato, Sara E.
    Jeruss, Jacqueline Sara
    Bethke, Kevin P.
    Hansen, Nora M.
    Khan, Seema Ahsan
    Von Roenn, Jamie H.
    Rosen, Steven T.
    Gradishar, William John
    Siziopikou, Kalliopi P.
    Meservey, Caitlin
    Kaklamani, Virginia G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] A phase II trial of docetaxel plus carboplatin plus bevacizumab as neoadjuvant therapy for triple negative breast cancer
    Chacon Lopez-Muniz, J. I.
    Cardenas, J. D.
    Santos Rodriguez, A. K.
    Esteban Esteban, M. C.
    Munoz Platon, E.
    Rubio Salvador, A. R.
    Alonso Soler, S. E.
    Fernandez Franco, L.
    San Juan del Moral, A.
    Burgueno Lorenzo, I.
    Trujillo Alba, B. L.
    Martinez Moreno, E.
    Moya Gomez, P.
    Cruz Mora, M. A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S283 - S283
12345